Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 5. Octet BLI competition assay using D25 and motavizumab.

Similar presentations


Presentation on theme: "Fig. 5. Octet BLI competition assay using D25 and motavizumab."— Presentation transcript:

1 Fig. 5. Octet BLI competition assay using D25 and motavizumab.
Octet BLI competition assay using D25 and motavizumab. (A) In a BLI assay, biosensor tips were dipped in pre-F, then into analyte, and then into competing antibody. D25 does not inhibit motavizumab binding to pre-F and vice versa, making these mAbs eligible for use in serum analysis. (B) Biosensor tips were dipped into pre-F, then into D25 or motavizumab, and then into sera. The mean percent inhibition of serum antibody binding by D25 is ~40%, and that by motavizumab is ~60%. Unlike motavizumab, there is increasing inhibition by D25 with increasing NT titers. The dashed line represents background binding inhibition. (C) A moderate correlation is found between percent binding inhibited by D25 and reciprocal EC50 NT titers, and a weak inverse correlation was found between percent binding blocked by motavizumab and NT titers. Joan O. Ngwuta et al., Sci Transl Med 2015;7:309ra162 Copyright © 2015, American Association for the Advancement of Science


Download ppt "Fig. 5. Octet BLI competition assay using D25 and motavizumab."

Similar presentations


Ads by Google